AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Enabling Genomic Testing in Cancer of Unknown Primary

Recruitingn/aAges 16 Years - anyAllThe Christie NHS Foundation Trust
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

Cancer of Unknown Primary (CUP) is where cancer cells are found in the body but the place the cancer began is not known. It is the 6th leading cause of cancer death in the UK and the prognosis is poor with a median survival of 6-9 months. There is a higher than average incidence of CUP in the North West (NW) of England (population of 7.4 million). Precision medicine has transformed treatment strategies in known tumour types, however in CUP there remains an urgent need to better understand CUP molecular characteristics to establish potential roles for novel therapeutic strategies. Treatment options remain limited due to difficulties in determining the primary site of the tumour and the lack of access to validated biomarkers. Access to good-quality tissue for molecular profiling remains a huge challenge in CUP. The emergence of liquid biopsies (sequence DNA in a blood test) as a source of

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: 1. Aged 16 years or over 2. Written informed consent according to ICH/GCP and national regulations 3. ECOG Performance status 0-2 4. Confirmed diagnosis of CUP as per the ESMO guidelines. Patients must have; 1. The local pathology reports confirming compatibility with CUP diagnosis and the associated slides used for the diagnosis 2. Discussion at a local CUP MDT confirming diagnosis 5. Availability of archival tumour histological report 6. Willingness to provide blood samples on up to two occasions during the study Exclusion Criteria: 1. Patient with an immunohistochemistry profile that provides a definitive clinical indication of a primary cancer with a specific treatment 2. Known HIV, Hepatitis B, C positive, due to the difficulties in handling high-risk specimens 3. Patients who are unable to provide fully informed written consent 4. Presence of any medical, psychological, familial or sociological condition that, in the investigator's opinion, will hamper compliance with the study protocol and follow-up schedule 5. Bleeding diathesis (patients' on anticoagulation are permitted to enter the trial if anticoagulation can be safely managed to enable blood sampling) 6. Conditions in which blood sampling may increase risk of complications for the patients and/or investigator
๐Ÿ’Š

What it tests

  • Gene panel array
  • Blood Sample Collection
๐Ÿ“

Where

6 sites
The Christie NHS Foundation Trust
Manchester, United Kingdom
The Clatterbridge Cancer Centre NHS Foundation Trust
Liverpool, United Kingdom
Blackpool Teaching Hospitals NHS Foundation Trust
Blackpool, United Kingdom
Northern Care Alliance NHS Foundation Trust
Manchester, United Kingdom
University Hospitals of Morecambe Bay NHS Trust
Morecambe, United Kingdom
Lancashire Teaching Hospitals NHS Foundation Trust
Preston, United Kingdom
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy